Skip to content

Deanna McLeod: OHIP Data Show Jumps in Bell’s Palsy, PE, Myocarditis

Day 4 · 3:48:49 · Myriam Bohémier · Dean Allison · Deanna McLeod · Nicole Sedore

  • 📊 Ontario billing for 16 million people shows clear post-rollout rises in Bell’s palsy community and hospital care.
  • 🩸 Hospital pulmonary-embolism rates climbed 13 %, well above chance boundaries.
  • ❤️ Myocarditis codes surged 87 % and 76 % in 2021-22, contradicting ‘rare and transient’ claims.

Recalled expert presents hard health-seeking data.

← Carol Pierce Security Video and Final Texts Before Sudden Death | Emergency Rolling Reviews Replaced Proper Safety Testing →

Transcript

Myriam Bohémier · 3:48:49

And so Deanna, would you please take the Bible in your right hand. Deanna McLeod, do you swear to tell the truth, the whole truth, and nothing but the truth? So help you God. I'll just ask you, we've got about 13 minutes, to use that time wisely and continue your presentation.

Dean Allison · 3:49:22

Of—.

Deanna McLeod · 3:49:23

Oh, Kaleidoscope Strategic Medical Research firm, 20 years of doing evidence-based evaluations and trying to counter pharmaceutical bias and preparing guidelines for cancer.

Myriam Bohémier · 3:49:34

And I'm pressing my slide thing and it is not working.

Deanna McLeod · 3:49:41

Hey, okay. So I'm just going to show you a few more slides. We got through part of them yesterday. The slide on the left is a slide for Bell's palsy. So a number of the people who reported injuries, neurological injuries following the mRNA vaccine. So you can see on the left-hand slide, that is OHIP data, which represents the billing data for 16 million people in Ontario, Canada. This is basically health utility data or access to care data. So you can see that up until the COVID-19, uh, mRNA product rollout, you had a steady state. Whenever we went into lockdowns, it drops down, there's a rebound. Those are the white dots. And then after that, going to the right, you can see that there's an elevation in the number of people on a monthly basing basis seeking care for Bell's palsy.

Deanna McLeod · 3:50:45

So if you were to look at the steady line in the middle, that would be what would be expected during that time. And those little blue dots are all of the increases in what would be expected at that time. And these are monthly rates. So let's just look at that. So we would say maybe 7 or 8 people would be expected to be looking for care for Bell's palsy in a given time. And then we have a jump up to 9, 10, at any given point. And the gray band is what would be due to chance, and what's above the band would be something that would unlikely be due to chance.

Nicole Sedore · 3:51:19

Right.

Myriam Bohémier · 3:51:19

And when you see numbers like 7, that's per 100,000 of the population.

Deanna McLeod · 3:51:23

7, Yes, thank you. 7 Per 100,000 per month. So if you add that to a year, that would be many more. On the right-hand side, you have health-seeking behavior, accessing health hospital care. So they don't do it on a per-patient basis for that. So the hospital care would be, you know, there's an event at the hospital and it's either going up or down. So you can see for Bell's palsy in the hospital, there's a trend towards increased need, but then with 2020 and 2021, you see an increase, especially in 2021, and that represents a 4% increase. So one is community care, the other one is hospital care. So you have to kind of look at both of those if you want to understand the trends. So pulmonary embolisms, there's been lots of talks about clotting, uh, over the inquiry. And so you can see here on the left-hand side, when you're looking at community care, you've got a trend going up, and the lines don't necessarily align very well except for maybe whenever the vaccine was rolled out initially.

Deanna McLeod · 3:52:26

But if you look at the hospital care you can actually see that there's a 13% increase in pulmonary embolism. So those are fatal clots or could be potentially fatal clots going to the lungs. So pulmonary embolism, that's an increase of 13%. It's well above the boundary of something that would be due to chance. So if you were somebody who would be wanting to know what the actual rate of side effects were for an mRNA product, there's a lot of talk about the QIFAS, which is the passive surveillance system in Canada. But this is much more reliable data because you can't skew this. This is people actually looking for care for these actual conditions.

Myriam Bohémier · 3:53:05

And I have to stop because we get witness after witness saying they couldn't get care. So this is actual data for witnesses who got care with the province of Ontario.

Deanna McLeod · 3:53:14

When I'm saying care, that's like health-seeking behavior. I have a problem. The doctor comes in, sees them, and then they have to bill for that interaction. And so what they bill is it's pulmonary embolism. Or I'm billing for Bell's palsy. So this is a qualified medical professional making a diagnosis and assigning a diagnostic code. So it's unlikely, I mean, maybe some people won't bill or maybe they bill incorrectly, but those billing inconsistencies would be consistent over time.

Myriam Bohémier · 3:53:43

It's not like they would change during COVID What I was getting at, we have witnesses being sent away from ER without any diagnostic at all that by And it keeps repeating, but then later on they're diagnosed with these conditions. So it's just, it's an interesting twist.

Deanna McLeod · 3:53:59

So this is hospital care data. I'm going to keep going. This is hospital care data for myocarditis. There's various codes for myocarditis or hospital codes for myocarditis. You can see on the right-hand side, the one, this is annual numbers now. It's fairly consistent, but then you have the mRNA product rollout. You see this big jump. It's above the boundaries for chance. On the right-hand side is another code for myocarditis. It's consistent again, mRNA rollout, big jump in 2021 and again in 2022. These represent increases of 87% and 76%. And so a lot of the talking points that we've heard have been that myocarditis is rare and transient. I would probably argue that the data for 16 million people in Ontario would say something other than that. I'd just like to go through, uh, this is just a timeline of the data that came out at various time points for myocarditis.

Deanna McLeod · 3:54:59

So this is one of the, the side effects that was attributed to the vaccine.